tetrahydrozoline, ophthalmic (Visine Advanced Relief, Visine Maximum Redness Relief, Visine Original, Rohto Arctic)
Classes: Decongestants, Ophthalmic; Adrenergic Agonists
- Dosing and uses of Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic)
- Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic) adverse (side) effects
- Warnings
- Pregnancy
- Pharmacology of Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic)
Dosing and uses of Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic)
Adult dosage forms and strengths
ophthalmic drops
- 0.05%
Conjunctival Congestion
Temporary relief of ocular redness caused by irritation & relief of burning or irritation caused by dry eyes
1-2 gtt to affected eye q6-12hr
Not to exceed 72 hours of use
Administration
Remove contact lenses before use
Do not use if this solution changes color or becomes cloudy
Do not touch tip of container to any surface to avoid contamination
Replace cap after each use
Pediatric dosage forms and strengths
Safety and efficacy not established
Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic) adverse (side) effects
Frequency not defined
Irritation/burning
Blurred vision
Headache
Tremor
Hypertension
Tachycardia
Palpitation
Warnings
Contraindications
Hypersensitivity
Cautions
Narrow angle glaucoma
May cause temporary mydriasis
Use caution in hypertension, coronary artery disease, diabetes, and hyperthyroidism
Discontinue and seek medical advice if the following occur: eye pain, changes in vision, redness or irritation of the eye lasts >72 hr
Pregnancy and lactation
Pregnancy category: C
Lactation: not known if distributed in milk
Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic)
Mechanism of action
May stimulate alpha-adrenergic receptors in the arterioles of the conjunctiva; produces vasoconstriction
May produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants
Pharmacokinetics
Duration: 2-3hr (vasoconstriction)